Since ACTBL2 expression was shown to be associated with an impaired prognosis of ovarian cancer patients, putatively enhanced by its promigratory characteristics, a reduction of intracellular levels of ACTBL2 might result in prognostically favorable alterations in tumor biology. This evidence concerns the gene ACTBL2 and ovarian carcinoma.